Italia markets closed

Novo Nordisk A/S (NONOF)

Other OTC - Other OTC Prezzo differito. Valuta in USD.
Aggiungi a watchlist
106,09-1,23 (-1,15%)
Al 01:47PM EDT. Mercato aperto.
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente107,32
Aperto109,26
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno104,50 - 109,75
Intervallo di 52 settimane90,58 - 123,70
Volume1.335
Media Volume31.216
Capitalizzazione239,844B
Beta (5 anni mensile)0,26
Rapporto PE (ttm)35,01
EPS (ttm)3,03
Prossima data utiliN/D
Rendimento e dividendo (forward)1,57 (1,46%)
Data ex dividendo25 mar 2022
Stima target 1AN/D
  • GlobeNewswire

    Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

    Bagsværd, Denmark, 8 August 2022 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated per

  • GlobeNewswire

    Novo Nordisk's sales increased by 25% in Danish kroner and by 16% at constant exchange rates to DKK 83.3 billion in the first six months of 2022

    3 August 2022 - Financial report for the period 1 January 2022 to 30 June 2022 Novo Nordisk's sales increased by 25% in Danish kroner and by 16% at constant exchange rates to DKK 83.3 billion in the first six months of 2022 Operating profit increased by 26% in Danish kroner and by 14% at constant exchange rates (CER) to DKK 37.5 billion.Sales in International Operations increased by 15% in Danish kroner (10% at CER), and sales in North America Operations increased by 36% in Danish kroner (24% at

  • GlobeNewswire

    Novo Nordisk A/S – Share repurchase programme

    Bagsværd, Denmark, 3 August 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme initia